Tibsovo Market Report 2026

Tibsovo Market Overview

• Tibsovo market size has reached to $1.08 billion in 2025 • Expected to grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Acute Myeloid Leukemia Cases Driving Market Growth Due To High Mortality And Increasing Awareness • Market Trend: Regulatory Approvals Driving Market Expansion And Leadership In IDH1-Mutated Cancers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tibsovo Market?

Tibsovo is an oral targeted therapy primarily used to treat adults with acute myeloid leukemia (AML) or cholangiocarcinoma that harbor a specific mutation in the IDH1 gene. By inhibiting the mutated IDH1 enzyme, tibsovo reduces the production of an abnormal metabolite that promotes cancer cell growth, thereby helping to restore normal cell differentiation and slow disease progression. The main types of products in tibsovo are tablets, capsules, combination therapy, and injectable forms. Tablets refer to the oral solid dosage form of the drug ivosidenib, designed for convenient, once-daily administration. These tablets are administered through oral administration and intravenous administration and distributed through hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used for applications such as cancer treatment, acute myeloid leukemia, chemotherapy, and targeted therapy, catering to diverse end users including hospitals, specialty clinics, research institutions, and homecare settings.

What Is The Tibsovo Market Growth Forecast?

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to development of novel oral targeted therapies, increasing genetic testing and personalized medicine adoption, expansion of combination treatment regimens, rising investment in oncology research, growth of hospital and specialty clinic networks. Major trends in the forecast period include rising adoption of targeted therapies for aml and cholangiocarcinoma, increasing use of oral targeted drugs over intravenous administration, expansion of combination therapy approaches, growing awareness of idh1 mutation testing, enhanced focus on personalized cancer treatment.

Global Tibsovo Market Segmentation

1) By Product: Tablets, Combination Therapy 2) By Drug Administration: Oral Administration, Intravenous Administration 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Cancer Treatment, Acute Myeloid Leukemia, Targeted Therapy 5) By End User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings Subsegments: 1) By Tablets: Oral Tablets, Extended-Release Tablets 2) By Combination Therapy: Tibsovo + Chemotherapy Agents, Tibsovo + Targeted Therapy Agents

What Is The Driver Of The Tibsovo Market?

The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the tibosovo market going forward. Acute myeloid leukemia (AML) refers to an aggressively progressing cancer of the blood and bone marrow that directly impacts blood cell production, immune function, and overall physical health. The prevalence of acute myeloid leukemia is increasing largely due to the global rise in the aging population, as the disease primarily affects older adults, and longer life expectancy means more individuals are reaching the age group most susceptible to developing this form of leukemia. Tibsovo helps acute myeloid leukemia by targeting IDH1-mutated cancer cells to inhibit abnormal cell growth, reduce disease progression, enhance treatment response, and improve survival outcomes by restoring normal blood cell production. For instance, in February 2023, according to the report published by the Leukemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults (25–65) are expected to be diagnosed with blood cancers, mainly including ALL, AML, and non-Hodgkin lymphoma. Therefore, the increasing prevalence of acute myeloid leukemia is driving the growth of the tibsovo industry.

Key Players In The Global Tibsovo Market

Major companies operating in the tibsovo market are Servier Laboratoires, Agios Pharmaceuticals

Global Tibsovo Market Trends and Insights

Major companies operating in the tibsovo market are focusing on obtaining regulatory approvals to broaden the drug’s reach and maintain its leadership in IDH1-mutated cancers. Regulatory approvals refer to official permissions granted by health authorities that allow a drug to be legally marketed and used for specific medical conditions after confirming its safety and effectiveness. For instance, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for tibsovo (ivosidenib tablets), marking it as the first and only IDH1-targeted therapy authorized in Europe for two challenging cancer types. It is approved for use in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) patients with an IDH1 R132 mutation who are ineligible for standard induction chemotherapy and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma harboring the same mutation after at least one prior systemic treatment. This approval, which benefits from orphan drug designation, addresses critical unmet medical needs and provides new hope for better outcomes and quality of life for these patients.

What Are Latest Mergers And Acquisitions In The Tibsovo Market?

In December 2023, Servier Group, a France-based pharmaceutical company that offers TIBSOVO (ivosidenib tablets) as a targeted therapy for patients with IDH1-mutated cancers, acquired exclusive rights to develop, manufacture, and commercialize TIBSOVO from CStone Pharmaceuticals for $44 million. This acquisition aims to strategically expand Servier Group’s footprint in the rapidly growing China and Singapore markets by securing exclusive rights to TIBSOVO, thereby enhancing its oncology portfolio with a targeted therapy for IDH1-mutated cancers and accelerating access to this innovative treatment for patients in these key regions. CStone Pharmaceuticals is a China-based biopharmaceutical company specializing in oncology treatments.

Regional Insights

North America was the largest region in the tibsovo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tibsovo Market?

The tibsovo market consists of sales of products including oral tablets, extended-release tablets, soft gel capsules, intravenous injection, and subcutaneous injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tibsovo Market Report 2026?

The tibsovo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tibsovo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.